Search Results
101 Results Found for “left ventricular dysfunction”
Native valve infective endocarditis (IE) is rare, with an incidence of 3–7 cases per 100,000 person-years.1,2 Cardiac structural complications from local infection extension include valvular destruction, peri-annular abscess and fistula formation. Left ventricular pseudoaneurysm (LVP) from IE is exceedingly rare, occurring in &...
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
From breakthrough prevention strategies to pivotal late-breaking trials, ACC.26 showcased the rapidly evolving future of cardiovascular care.
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
Late-breaking data from the Phase 3 HOPE-3 trial of deramiocel in Duchenne muscular dystrophy, presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, suggest potential benefits across cardiac and functional outcomes. The investigational first-in-class therapy is currently under review by the FDA for the treatment of DMD cardiomyopathy, with a Prescription Drug User Fee Act target action date of 22 August, 2026.
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
The FDA has approved aficamten for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), with the aim of improving functional capacity and symptoms.
Epicardial adipose tissue (EAT) is a fat collection directly adjacent to the myocardium and coronary vasculature, lacking any separation and sharing the same circulation.1,2Â This anatomy enables direct signalling between EAT and the surrounding tissue, positioning EAT as a central ...
Cardiovascular medicine stands at a pivotal crossroads—shaped by rapid advances in precision therapies, a deepening understanding of disease mechanisms, and an urgent imperative to address global health disparities. As the burden of cardiovascular disease continues to evolve, so too ...
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac abnormality characterized by left ventricular hypertrophy and diastolic dysfunction, primarily attributed to mutations in genes that encode sarcomeric proteins.1,2 The disease manifests in two broad phenotypes: obstructive HCM (oHCM), defined by dynamic left ...
Conduction system pacing (CSP) is being increasingly adopted as a more physiological alternative to right ventricular and biventricular pacing and is an integral part of the European Heart Rhythm Association (EHRA) core curriculum for the device specialist.1–6 Left bundle branch ...
Tricuspid regurgitation (TR) is a frequent finding on echocardiography, with detection rates reaching up to 86% across the different ranges of severity, with moderate or greater TR being reported in at least 6–8% of patients.1–3 The prevalence of TR increases with age, ...
Cardiovascular disease (CVD) is a significant cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). An estimated 60–80% of patients with T2DM die of cardiovascular events.1,2 A bidirectional relationship has been noted between heart failure (HF) ...
In this interview, Dr. Margarida Pujol-Lopez from the Hospital Clinic in Barcelona discusses the differences between conduction system pacing (CSP) and biventricular pacing (BVP) in treating heart failure. CSP is more physiological and may offer better outcomes than BVP, which fails in about 30% of patients. The CONSYST-CRT trial, comparing CSP and BVP, showed that CSP is non-inferior to BVP based on primary and secondary endpoints, including mortality, heart failure, and QRS shortening.
Revascularization for patients with ischaemic left ventricular (LV) systolic dysfunction takes one of two forms - percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG), both of which have positives and negatives. STICH, published in 2011, analysed the role of CABG in patients with LV systolic dysfunction and looked at improvement of clinical outcomes in 1,212 patients from 22 countries across the world, optimised to either optimal medical therapy or optimal medical therapy plus CABG. REVIVED-BCIS2 in 2022 looked at 700 patients in the UK with a similar patient population of 35% ejection fraction or less, randomized to PCI or optimal medical therapy. This interview dives into their analysis of the results from these exciting trials and investigation into the discrepancies between the outcomes.
The Ground-BrEAking Electroporation-based inTervention for Atrial Fibrillation (BEAT-AF) treatment project is an initiative funded by the European Commission from the European Union's Horizon 2020 research and innovation programme, and managed under the European Health and Digital Executive Agency (grant number 945125).1,2Â The ...
Highlights The autonomic nervous system plays a critical role in the aetiopathogenesis of atrial fibrillation (AF). Neuromodulation of the autonomic nervous system has been a topic of increased interest in the management of AF. Ablation of ganglionated plexi, ethanol ablation ...
Infiltrative cardiomyopathies are a diverse group of cardiac diseases caused by the deposition of abnormal substances within the myocardium and include diseases, such as Fabry disease, sarcoidosis and less common genetic diseases, such as Friedreich’s ataxia and Danon disease.1 ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
